Similar articles

• Improved survival with ipilimumab in patients with metastatic melanoma.

  Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Hodi FS, et al. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
• Diarrhea from ipilimumab in melanoma.

  Schwartz JD. Schwartz JD. N Engl J Med. 2010 Dec 2;363(23):2262; author reply 2262-3. doi: 10.1056/NEJMc1010475. N Engl J Med. 2010. PMID: 21121842 No abstract available.
• Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

  Tarhini AA, Kirkwood JM. Tarhini AA, et al. Curr Opin Mol Ther. 2007 Oct;9(5):505-14. Curr Opin Mol Ther. 2007. PMID: 17932815 Review.
• Ipilimumab.

  Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Sondak VK, et al. Nat Rev Drug Discov. 2011 Jun;10(6):411-2. doi: 10.1038/nrd3463. Nat Rev Drug Discov. 2011. PMID: 21629286 No abstract available.
• [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].

  Robert C, Mateus C. Robert C, et al. Med Sci (Paris). 2011 Oct;27(10):850-8. doi: 10.1051/medsci/20112710013. Epub 2011 Oct 21. Med Sci (Paris). 2011. PMID: 22027422 Review. French.